An Open-label, Single Centre, Single Oral Dose Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs HTL 0014242 (Primary)
- Indications Neurological disorders; Psychiatric disorders
- Focus Pharmacokinetics
- Sponsors Heptares Therapeutics
- 06 Jul 2021 Status changed from recruiting to completed.
- 15 Apr 2021 Planned End Date changed from 21 Mar 2021 to 25 Aug 2021.
- 15 Apr 2021 Planned primary completion date changed from 21 Mar 2021 to 25 Aug 2021.